Update S3-guideline "Colorectal cancer" 2008;S3-Leitlinie "Kolorektales Karzinom" - Aktualisierung 2008

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 8, 2008, Pages 799-840

  Schmiegel, Wolff ^a   Reinacher Schick, A ^a   Arnold, D ^a   Graeven, U ^a   Heinemann, V ^a   Porschen, R ^a   Riemann, J ^a   Rodel C ^a   Sauer, R ^a   Wieser, M ^a   Schmitt, W ^a   Schmoll, H J ^a   Seufferlein, T ^a   Kopp, I ^a   Pox, C ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB;

ADJUVANT THERAPY; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; COLONOSCOPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; ENDOSCOPY; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; PERIOPERATIVE PERIOD; SIGMOIDOSCOPY; TREATMENT INDICATION;

EID: 52149083741     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027726     Document Type: Article

References (330)

1. Schmiegel W et al. Kolorektales Karzinom: Prävention und Früherkennung in der asynmptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol 2000; 38: 49-76
2. Schmiegel W et al. S3-Guidelines Conference "Colorectal Carcinom" 2004. Z Gastroenterol 2004; 42 (10): 1129-1177
3. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345 (8): 555-560 (EBM-Grad: III b)
4. Imperiale TF et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343 (3): 169-174 (EBM-Grad: III b)
5. Pickhardt PJ et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349 (23): 2191-2200 (EBM-Grad: I b)
6. Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours. Lyon: IARC Press, 2000
7. Kiesslich R et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124 (4): 880-888 (EBM-Grad: I b)
8. Rex DK et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2002; 97 (6): 1296-1308
9. Barclay RL et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355 (24): 2533-2541 (EBM-Grad: II b)
10. Simmons DT et al. Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time. Aliment Pharmacol Ther 2006; 24 (6): 965-971 (EBM-Grad: III b)
11. Lieberman D. A call to action - measuring the quality of colonoscopy. N Engl J Med 2006; 355 (24): 2588-2589
12. Robertson DJ et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005; 129 (1): 34-41 (EBM-Grad: III b)
13. Hosokawa O et al. Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 2003; 35 (6): 506-510 (EBM-Grad: III b)
14. Bressler B et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 2004; 127 (2): 452-456 (EBM-Grad: III b)
15. Leaper M et al. Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy 2004; 36 (6): 499-503 (EBM-Grad: III b)
16. Pabby A et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005: 61(3): 385-91 (EBM-Grad: III b)
17. Cotton PB et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. Jama 2004; 291 (14): 1713-1719 (EBM-Grad: I b)
18. Rockey DC et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005; 365 (9456): 305-311 (EBM-Grad: I b)
19. Halligan S et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 2005; 237 (3): 893-904 (EBM-Grad: I a)
20. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005; 142 (8): 635-650 (EBM-Grad: I a)
21. Johnson CD et al. Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps. Clin Gastroenterol Hepatol 2004; 2 (4): 314-321 (EBM-Grad: I b)
22. Purkayastha S et al. Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a metaanalysis. Clin Radiol 2005: 60(9): 980-989 (EBM-Grad: II a)
23. Hartmann D et al. Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology 2006: 238 (1): 143-149 (EBM-Grad: II b)
24. Florie J et al. MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer. Radiology 2007; 243(1): 122-131 (EBM-Grad: I b)
25. Morrin MM et al. Virtual colonoscopy: a kinder, gentler colorectal cancer screening test? Lancet 1999; 354 (9184): 1048-1049
26. Morrin MM et al. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. Dis Colon Rectum 2000; 43 (3): 303-311 (EBM-Grad: IV)
27. Neri E et al. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy. Radiology 2002; 223 (3): 615-619 (EBM-Grad: IV)
28. Hartmann D et al. Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon. Endoscopy 2005; 37 (9): 816-820 (EBM-Grad: IV)
29. Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield. Gastrointest Endosc 2004; 60(3): 408-413 (EBM-Grad: III b)
30. Karajeh MA, Sanders DS, Hurlstone DP. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients. Endoscopy 2006; 38 (3): 226-230 (EBM-Grad: III b)
31. Hurlstone DP et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective "back-to-bac" endoscopic study. Am J Gastroenterol 2005: 100 (10): 2167-2173 (EBM-Grad: II b)
32. Hurlstone DP et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005; 37 (12): 1186-1192 (EBM-Gtad: III b)
33. Lee JH et al. Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine. Am J Gastroenterol 2003; 98 (6): 1284-1288 (EBM-Grad: II b)
34. Hurlstone DP et al. Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy. Gut 2004; 53 (3): 376-380 (EBM-Grad: I b)
35. Trecca A et al. Advanced diagnostic tools: virtual colonoscopy and magnifying chromoendoscopy. Tech Coloproctol 2004; 8 (Suppl 2): s279-s282
36. Lapalus MG et al. Does chromoendoscopy with structure enhancement improve the colonoscopic adenoma detection rate? Endoscopy 2006; 38 (5): 444-448 (EBM-Grad: I b)
37. Kudo S et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J Surg 2000; 24(9): 1081-1090.
38. Kiesslich R et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33 (12): 1001-1006 (EBM-Grad: VI b)
39. Kudo S et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 2001; 33 (4): 367-373 (EBM-Grad: III b)
40. Brooker JC et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 56 (3): 333-338 (EBM-Grad: I b)
41. Eisen GM et al. High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study. Gastrointest Endosc 2002; 55 (6): 687-694 (EBM-Grad: IV)
42. Tsuda S et al. Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study. Gut 2002; 51 (4): 550-555 (EBM-Grad: II b)
43. Bianco MA et al. Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery. Endoscopy 2006; 38 (5): 470-476 (EBM-Grad: IV)
44. Kato S et al. Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions. World J Gastroenterol 2006; 12 (9): 1416-1420 (EBM-Grad: III b)
45. Hurlstone DP et al. Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy. Colorectal Dis 2004; 6(5): 369-375 (EBM-Grad: II b)
46. Hurlstone DP et al. Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis. Gut 2004; 53(2): 284-290 (EBM-Grad: II b)
47. Chiu HM et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007; 56(3): 373-379 (EBM-Grad: II b)
48. Dekker E et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007; 39(3): 216-221 (EBM-Grad: II b)
49. Su MY et al. Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps. Am J Gastroenterol 2006; 101 (12): 2711-2716 (EBM-Grad: IV)
50. Kiesslich R et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127 (3): 706-713 (EBM-Grad: IV)
51. Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies. Dis Colon Rectum 1986; 29 (12): 825-830 (EBM-Grad: IV)
52. Reiertsen O et al. Complications of fiberoptic gastrointestinal endoscopy - five years' experience in a central hospital. Endoscopy 1987; 19 (1): 1-6 (EBM-Grad: IV)
53. Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15 (4): 347-351 (EBM-Grad: IV)
54. Waye JD, Kahn O. Auerbach ME. Complications of cobonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996; 6 (2): 343-377 (EBM-Grad: IV)
55. Hsieh YH et al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology 2001; 48 (41): 1379-1382 (EBM-Grad: I b)
56. Karita M, Cantero D, Okita K. Endoscopic diagnosis and resection treatment for flat adenoma with severe dysplasia. Am J Gastroenterol 1993; 88 (9): 1421-1423 (EBM-Grad: IV)
57. Kudo S et al. Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 1997; 21(7): 694-701
58. Heldwein W et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy 2005; 37 (11): 1116-1122 (EBM-Grad: III b)
59. Di Giorgio P et al. Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study. Endoscopy 2004; 36 (10): 860-863 (EBM-Grad: I b)
60. Dobrowolski S et al. Prophylactic submucosal saline-adrenaline injection in colonoscopic polypectomy: prospective randomized study. Surg Endosc 2004; 18 (6): 990-993 (EBM-Grad: I b)
61. Katsinelos P et al. Endoloop-assisted polypectomy for large pedunculated colorectal polyps. Surg Endosc 2006; 20(8): 1257-1261 (EBM-Grad: IV)
62. Paspatis GA et al. A prospective, randomized comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of postpolypectomy bleeding in large colonic polyps. Am J Gastroenterol 2006; 101 (12): 2805; quiz 2913 (EBM-Grad: I b)
63. Shioji K et al. Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy. Gastrointest Endosc 2003; 57 (6): 691-694 (EBM-Grad: I b)
64. Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40(4): 458-462
65. Hui AJ et al. Risk of cobonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59(1): 44-48 (EBM-Grad: IV)
66. Yousfi M et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99 (9): 1785-1789 (EBM-Grad: III b)
67. Ernst A et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129 (3): 734-737 (EBM-Grad: IV)
68. Hurlstone DP et al. A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery. Colorectal Dis 2005; 7 (4): 339-344 (EBM-Grad: IV)
69. Gondal G et al. Biopsy of colorectal polyps is not adequate for grading of neoplasia. Endoscopy 2005; 37 (12): 1193-1197 (EBM-Grad: IV)
70. Waye JD et al. Small colon polyps. Am J Gastroenterol 1988; 83 (2): 120-122
71. O'Brien MJ et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98 (2): 371-379
72. Nusko G et al. Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis 1997; 12 (5): 267-271
73. Bond JH. Clinical relevance of the small colorectal polyp. Endoscopy 2001; 33 (5): 454-457
74. Arumugam PJ et al. Severe dysplastic lesions in the colon - how aggressive should we be? Colorectal Dis 2002; 4 (5): 345-347
75. Gschwantler M et al. High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. Eur J Gastroenterol Hepatol 2002; 14 (2): 183-188 (EBM-Grad: IV)
76. Burton S et al. Reliability of pre-operative biopsies in the histological grading of colorectal adenocarcinomas. Ann R Coll Surg Engl 2003; 85 (1): 23-25 (EBM-Grad: IV)
77. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50 (1): 113-130
78. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50 (1): 131-150
79. Deinlein P et al. Risk factors for lymphatic metastasis from pT1 colorectal adenocarcinoma. Pathologe 2003; 24 (5): 387-393 (EBM-Grad: III a)
80. Hermanek P. Polypectomy in the colorectum: histological and oncological aspects. Endoscopy 1983; 15: 158-161
81. Kikuchi R et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995; 38 (12): 1286-1295
82. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002; 45 (5): 628-634 (EBM-Grad: IV)
83. Fruhmorgen P et al. Endoscopic Therapy of Early Colorectal Cancer (pT1) - A Prospective Study. Z Gastroenterol 2003; 41(8): 703-710.
84. Frühmorgen P et al. Kolorektale Polypen, in Empfehlungen der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) für die Durchführung endoskopischer Untersuchungen. 2000: 127-134
85. Okabe S et al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg 2004; 8 (8): 1032-1039; discussion 1039-1040 (EBM-Grad: IV)
86. Yamamoto S et al. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepatogastroenterology 2004; 51 (58): 998-1000 (EBM-Grad:: IV)
87. Hassan C et al. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum 2005; 48 (8): 1588-1596 (EBM-Grad: III b)
88. Ueno H et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127 (2): 385-394 (EHM-Grad: III b)
89. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1 2002. Gastrointest Endosc 2003; 58 (6 Suppl): S3-S43
90. Nascimbeni R et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002; 45 (2): 200-206 (EBM-Grad: IV)
91. Seitz U et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004; 47 (11): 1789-1796; discussion 1796-1797 (EBM-Grad: IV)
92. Provenzate D et al. Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps. Ann Intern Med 1990; 113: 760-763 (EBM-Grad: IV)
93. Rex DK et al. Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects. Gastroenterology 1992; 102: 317-319 (EBM-Grad: IV)
94. Sciallero S et al. Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Gastrointest Endosc 1997; 46 (2): 124-130 (EBM-Grad: IV)
95. Koide N et al. A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up. Endoscopy 2002; 34 (6): 499-502 (EBM-Grad: IV)
96. Bressler B et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007; 132 (1): 96-102 (EBM-Grad: III b)
97. Sawhney MS et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131 (6): 1700-1705 (EBM-Grad: IV)
98. Winawer SJ et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130 (6): 1872-1885
99. Higaki S et al. Long-term follow-up of large flat colorectal tumors resected endoscopically. Endoscopy 2003; 35 (10): 845-849 (EBM-Grad: IV)
100. Regula J et al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study. Endoscopy 2003; 35 (3): 212-218 (EBM-Grad: IV)
101. Seitz U et al. Long-term results of endoscopic removal of large colorectal adenomas. Endoscopy 2003; 35 (8): S41-S44 (EBM-Grad: IV)
102. Boix J et al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective? Dig Dis Sci 2007; 52 (3): 840-844 (EBM-Grad: IV)
103. Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348 (10): 891-899 (EBM-Grad: I b)
104. Benamouzig R et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125 (2): 328-336
105. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348 (10): 879-880
106. Arber N et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355 (9): 885-895
107. Baron JA et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131 (6): 1674-1682 (EBM-Grad: I b)
108. Bertagnolli MM et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355 (9): 873-884 (EBM-Grad: I b)
109. Bresalier RS et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352 (11): 1092-102 (EBM-Grad: I b)
110. Solomon SD et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352 (11): 1071-1080 (EBM-Grad: I b)
111. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006; 355 (9): 950-952
112. Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2005; 3: CD003548 (EBM-Grad1 a)
113. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. Jama 1990; 264 (11): 1444-1450
114. Compton C et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88 (7): 1739-1757
115. Le Voyer TE et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21 (15): 2912-2919
116. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20(19): 3992-3998
117. Lonardi S, Stefani M, Jirillo A, Ghiotto C et al. Benefit of fluorouracil and folinic acid adjuvant in colon cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (No 18S): 13564
118. Sargent DJ et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345(15): 1091-1097
119. Popescu RA et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17 (8): 2412-2418
120. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. J Clin Oncol 2006; 24 (25): 4085-4091 (EBM-Grad: I b)
121. Fata F et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 2002; 94 (7): 1931-1938
122. Francini G et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106 (4): 899-906
123. O'Connell MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15 (1): 246-250.
124. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997; 40 (1): 35-41
125. Gill S et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22 (10): 1797-1806 (EBM-Grad: I a)
126. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955): 939-944
127. Figueredo A et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1 (5): 379-392
128. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17 (5): 1356-1363
129. Mamounas E et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17 (5): 1349-1355
130. Benson 3rd AB et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22 (16): 3408-3419 (EBM-Grad: I a)
131. Quasar Collaborative G et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370 (9604): 2020-2029 (EBM-Grad: I b)
132. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4007
133. Moertel CG et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13 (12): 2936-2943
134. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85 (10): 1437-1443
135. Schrag D et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20 (19): 3999-4005
136. Merkel S et al. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001; 92 (6): 1435-1443
137. Petersen VC et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51 (1): 65-69
138. Morris M et al. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93 (7): 866-871 (EBM-Grad: IV)
139. Burdy G et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44 (11): 1682-1688
140. Jestin P et al. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005; 92 (1): 94-100 (EBM-Grad: IV)
141. McArdle CS, McMillan DC, Hole DJ. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 2006; 93 (4): 483-488 (EBM-Grad: IV)
142. Caplin S et al. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83 (4): 666-672
143. George S et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006; 95 (7): 841-847 (EBM-Grad: II b)
144. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006; 244 (4): 602-10 (EBM-Grad: IV)
145. Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322 (6): 352-358
146. Hermanek P, Hutter RV, Sobin LH. Prognostic grouping: the next step in tumor classification. J Cancer Res Clin Oncol 1990; 116 (5): 513-516
147. Martinez-Lopez E et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114 (6): 1180-1187
148. Ogunbiyi OA et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16 (2): 427-433
149. Jernvall P et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999; 79 (5-6): 903-908
150. Font A et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001; 44 (4): 549-557
151. Diep CB et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 2003; 21 (5): 820-829
152. Carethers JM et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114 (6): 1188-1195
153. Lanza G et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24 (15): 2359-2367 (EBM-Grad: II c)
154. Sinicrope FA et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131 (3): 729-737 (EBM-Grad: II c)
155. Araujo SE et al. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 2007; 50 (11): 1800-1810 (EBM-Grad: I a)
156. Ribic CM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (3): 247-257
157. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1 (2): 104-109
158. Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23): 2343-2351 (EBM-Grad: I b)
159. Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25 (16): 2198-2204 (EBM-Grad: I b)
160. Schmoll HJ et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25 (1): 102-109 (EBM-Grad: I b)
161. Van Cutsem E, Labianca R, Hossfeld D et al. PETACC 3, Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/ folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (No 16S): 8
162. Ychou M, Raoul J-L, Douillard J et al. For the GI Group of the FNCLCC and the FFCD. A phase III randomized trial of LV5FU2 +CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/ FFCD9802). ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (No 16S): 3502
163. Saltz LB et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25 (23): 3456-3461 (EBM-Grad: I b)
164. Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352 (26): 2696-2704 (EBM-Grad: I b)
165. Lembersky BC et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24 (13): 2059-2064 (EBM-Grad: I b)
166. Sakamoto J et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22 (3): 484-92 (EBM-Grad: I a)
167. Andre T, Quinaux E, Louvet C et al. GERCOR, Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (No 16S): 3522
168. Carrato A, Kohne C, Bedenne L et al. for AIO/CAO, FFCD, TTD, EORTC, Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. ASCO Annual Meeting Proceedings. J of Clin Oncol 2006; 24 (No 18S): 3563
169. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003: 21 (15): 2896-2903 (EBM-Grad: I b)
170. Arkenau HAT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005; 20 (3): 258-261 (EBM-Grad: I b)
171. Chau I et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16 (4): 549-557 (EBM-Grad: I b)
172. Poplin EA et al. Phase III Southwest Oncology Group 9415/ Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23 (9): 1819-1825 (EBM-Grad: I b)
173. O'Connell MJ et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16(1): 295-300.
174. Haller DG et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005: 23 (34): 8671-8678 (EBM-Grad: I b)
175. Engelen SM, Beets GL, Beets-Tan RG. Role of preoperative local and distant staging in rectal cancer. Onkologie 2007; 30 (3): 141-145 (EBM-Grad: III a)
176. Beets-Tan RG et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001; 357 (9255): 497-504
177. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243 (1): 132-139 (EBM-Grad: I b)
178. Junginger T et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir 2006; 131 (4): 275-284
179. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008; 47: 20-31
180. Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (9): 638-646
181. Rodel C, Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer. Recent Results Cancer Res 2005; 165: 221-230
182. Peeters KC et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246 (5):
183. Folkesson J et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23 (24): 5644-5650 (EBM-Grad: I b)
184. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007; 25 (8): 1014-1020 (EBM-Grad: IV)
185. Rengan R et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? J Clin Oncol 2005; 23 (22): 4905-4912 (EBM-Grad: IV)
186. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358 (9290): 1291-1304
187. Camma C et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 2000; 284 (8): 1008-1015
188. Frykholm GJ, Glimetius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36 (6): 564-572
189. Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17): 1731-1740 (EBM-Grad: I b)
190. Marijnen CA et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23 (9): 1847-1858 (EBM-Grad: II b)
191. Peeters KC et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J Clin Oncol 2005; 23(25): 6199-6206
192. Sebag-Montefiore D, Steele R, Quirke P et al. For the NCRI colorectal cancer study group and CRO7 participants. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (No 18S): 3511
193. Bujko K et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72 (1): 15-24 (EBM-Grad: I b)
194. Bujko K et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10): 1215-1223 (EBM-Grad: I b)
195. Marijnen CA et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19 (7): 1976-1984
196. Bosset JF et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355 (11): 1114-1123 (EBM-Grad: I b)
197. Gerard JP et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24 (28): 4620-4625 (EBM-Grad: I b)
198. Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 2007; 183 (5): 227-235
199. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312 (23): 1465-1472
200. Krook JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324 (11): 709-715
201. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304
202. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002; 54: 386-396
203. Marijnen CA et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55 (5): 1311-1320
204. O'Connell MJ et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507
205. Smalley SR et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24 (22): 3542-3547 (EBM-Grad: I b)
206. Tepper JE et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - final report of intergroup 0114. J Clin Oncol 2002; 20 (7): 1744-1750
207. Lee JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002; 20 (7): 1751-1758
208. Kim BITK, Lee J et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A final report. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4050
209. Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004; 13 (2-3): 93-101
210. Akasu T et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36 (4): 237-244 (EBM-Grad: I b)
211. Collette LBJ, den Dulk M et al. Patients with curative resection of cT3 - 4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386 (EBM-Grad: III b)
212. Lehnert TKH, Duck M et al. Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Br J Surg 1999; 86: 241-243
213. Saito Y et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002: 124 (5): 1007-1013
214. Pfannschmidt J et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003; 126 (3): 732-739
215. Lee WS et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22 (6): 699-704 (EBM-Grad: III b)
216. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84 (1): 324-338 (EBM-Grad: II a)
217. Poston GJ et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23 (28): 7125-7134 (EBM-Grad: II a)
218. Nordlinger B et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77 (7): 1254-1262
219. Fong Y et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15 (3): 938-946
220. Scheele J et al. Resection of colorectal liver metastases. What prognostic factors determine patient selection? Chirurg 2001; 72 (5): 547-560
221. Kato T et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46 (10 Suppl): S22-S31
222. Fong YFJ, Sun RL, Brennan MF et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230(3): 309-318; discussion 318-321
223. Joyce DL et al. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006; 141 (12): 1220-1226; discussion 1227 (EBM-Grad: II b)
224. Selzner M et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240 (6): 1027-1034: discussion 1035-1036 (EBM-Grad: II b)
225. Amthauer H et al. Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions. Nuklearmedizin 2006; 45 (4): 177-184 (EBM-Grad: II b)
226. Taylor RA, Turoto S, Akhurst TJ et al. Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score. Gastrointestinal Cancers Symposium 2007; Abstract No: 240
227. Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371 (9617): 1007-1016 (EBM-Grad: I b)
228. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23 (9): 2038-2048 (EBM-Grad: I a)
229. Lorenz M et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir 2003; 128 (2): 87-94
230. Wein A et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003; 64 (2): 131-138
231. Gruenberger B et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26 (11): 1830-1835 (EBM-Grad: II b)
232. Langer B, Bleiberg H, Labianca B et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. J Clin Oncol 2002; 21 (No 18S): 592
233. Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings. J Clin Oncol 2006: 24 (No 18S): 3524
234. Portier G et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24 (31): 4976-4982 (EBM-Grad: II a)
235. Parks R et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204(5): 753-761; discussion 761-763 (EBM-Grad: III b)
236. Figueras J et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88 (7): 980-985
237. Scheithauer W et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Bmj 1993; 306 (6880): 752-755
238. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992; 10 (6): 904-911
239. Mattioli R et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005:16 (7): 1147-1151 (EBM-Grad: IV)
240. Feliu J et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94 (7): 969-975 (EBM-Grad: IV)
241. Sastre J et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23 (15): 3545-3551 (EBM-Grad: II b)
242. Barrueco J, Marshall J, Mitchell E et al. Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients > 65 years compared with those > 65: THE BICC-C STUDY. ASCO ANNUAL MEETING PROCEEDINGS. J Clin Oncol 2007; 25 (No 18S): 4076
243. Folprecht G, Seymour M, Saltz L et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. J Clin Oncol 2008; 26: 1443-1451 (EBM-Grad: I a)
244. Grothey A et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22 (7): 1209-1214 (EBM-Grad: IV)
245. Giacchetti S et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10 (6): 663-669
246. Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13): 1670-1676 (EBM-Grad: I b)
247. Van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Annual Meeting Proceedings. J Clin Oncol 2007: 25 (No 18S): 4000
248. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting Proceedings. J Clin Oncol 2008; 26 (No 18S): 2
249. Folprecht G et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16 (8): 1311-1319 (EBM-Grad: I a)
250. Souglakos J et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94 (6): 798-805 (EBM-Grad: I b)
251. Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12): 2013-2019 (EBM-Grad: I b)
252. Aloia T et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24(31): 4983-4990 (EBM-Grad: IV)
253. Vauthey JN et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24 (13): 2065-2072 (EBM-Grad: II b)
254. Benoist S et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24 (24): 3939-3945 (EBM-Grad: IV)
255. Solbiati LLT, Goldberg SN et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221: 159-166
256. Vogl TJ, Straub R, Eichler K et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: 367-377
257. Kerr D, McArdle C, Ledermann J et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: amulticentre randomised trial. Lancet 2003; 361: 368-373
258. Gray B et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12 (12): 1711-1720
259. Lim L et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005; 5: 132 (EBM-GradII c)
260. Mancini R et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo 2006; 20 (6A): 711-714 (EBM-Grad: IV)
261. Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66 (Suppl 2): S62-S73 (EBM-Grad: III a)
262. Koopman M et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370 (9582): 135-142 (EBM-Grad: I b)
263. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 2007; 370 (9582): 105-107
264. Seymour MT et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370 (9582): 143-152 (EBM-Grad: I b)
265. Dy GK et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 2007; 25(23): 3469-3474 (EBM-Grad: IV)
266. Petrelli N et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7 (10): 1419-1426
267. Poon MA et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10): 1407-1418
268. Lokich JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7 (4): 425-432
269. de Gramont A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15 (2): 808-815
270. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16 (1): 301-308
271. Clarke DE, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990; 97 (4): 966-972
272. Prandoni P et al. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990; 20 (Suppl 1): 220-223
273. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19): 3665-3675
274. Liu G et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15 (1): 110-115
275. Borner MM et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38 (3): 349-358
276. Twelves C et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17 (2): 239-245 (EBM-Grad: II b)
277. Van Cutsem E et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21): 4097-4106 (EBM-Grad: I b)
278. Hoff PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (8): 2282-2292 (EBM-Grad: I b)
279. Van Cutsem E et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90 (6): 1190-1197 (EBM-Grad: I a)
280. Kohne CH et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13 (2): 308-317
281. de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16): 2938-2947
282. Giacchetti S et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24 (22): 3562-3569 (EBM-Grad: I b)
283. Giacchetti S et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18 (1): 136-147 (EBM-Grad: I b)
284. Douillard JY et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209): 1041-1047 (EBM-Grad: I b)
285. Kohne CH et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23 (22): 4856-4865 (EBM-Grad: I b)
286. Saltz LB et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-914
287. Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Clin Oncol 2004; 22 (2): 229-237 (EBM-Grad: I b)
288. Colucci G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23 (22): 4866-4875 (EBM-Grad: I b)
289. Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22 (1): 23-30 (EBM-Grad: I b)
290. Goldberg RM et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24 (21): 3347-3353 (EBM-Grad: I b)
291. Comella P et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005; 16 (6): 878-886 (EBM-Grad: I b)
292. Diaz-Rubio E et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25 (27): 4224-4230 (EBM-Grad: I b)
293. Porschen R et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25 (27): 4217-4223 (EBM-Grad: I b)
294. Cassidy J et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26 (12): 2006-2012 (EBM-Grad: I b)
295. Fuchs CS et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25 (30): 4779-4786 (EBM-Grad: I b)
296. Kohne CH et al. Irinotecan combined with infusional 5-fluorouracil/ folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19 (5): 920-926 (EBM-Grad: I b)
297. Schmiegel W, Reinacher-Schick A, Freier W et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/ oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (Caplri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4034
298. Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23 (16): 3697-3705 (EBM-Grad: I b)
299. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-2342 (EBM-Grad: I b)
300. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4035
301. Folprecht G et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17 (3): 450-456 (EBM-Grad: IV)
302. Tournigand C et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24 (3): 394-400 (EBM-Grad: I b)
303. Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTI-MOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4013
304. Maughan TS et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361 (9356): 457-464 (EBM-Grad: I b)
305. Labianca RIF, Cortesi E et al. Italian Group for the Study of Digestive Tract Can, Alternating versus continuous "FOLFIR" in advanced colorectal cancer (ACC): A randomized "GISCA" trial. ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (No 18S): 3505
306. Cunningham D et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1413-1418 (EBM-Grad: I b)
307. Rougier P et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407-1412 (EBM-Grad: I b)
308. Rothenberg ML et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21(11): 2059-2069 (EHM-Grad: I b)
309. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (4): 337-345 (EBM-Grad: I b)
310. Sobrero AF, Fehrenbacher L, Maurel J et al. EPIC: Randomized Phase III trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2008; 26: 2311-2319 (EBM-Grad: I b)
311. Giantonio BJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12): 1539-1544 (EBM-Grad: I b)
312. Rothenberg MLMN, Butts C et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4031
313. Eng C, Maurel J, Scheithauer W et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (No 18S): 4003
314. Rao S et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004; 91 (5): 839-843 (EBM-Grad: IV)
315. Chong G et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93 (5): 510-514 (EBM-Grad: IV)
316. Lim DH et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005; 56(1): 10-14 (EBM-Grad: IV)
317. Alliot C. Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2006; 94 (6): 935-936; author reply 937
318. Lenz HJ et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24 (30): 4914-4921 (EBM-Grad: II c)
319. Jonker DJ, Karapetis CS, O'Callaghan J et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med 2007; 357: 2040-2048 (EBM-Grad: I b)
320. Lievre A et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26 (3): 374-379 (EBM-Grad: IV)
321. Hecht JR et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110 (5): 980-988 (EBM-Grad: IV)
322. Van Cutsem E et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-1664 (EBM-Grad: I b)
323. Amado R, Wolf M, Peeters M. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2008; 26: 1626-1634 (EBM-Grad: IV)
324. Lehnert TGM. Posterior pelvic exenteration in locoregional recurrence of rectal carcinoma - indications, technique and outcome. Chirurg 2001; 72: 1393-1401
325. Shibata D, Paty P, Guillem JG et al. Surgical management of isolatedretroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 2002; 45: 795-801
326. Koppe MJ, Boerman O, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243 (2): 212-222 (EBM-Grad: III a)
327. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743
328. Wu JS, Wong R, Johnston M et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605
329. Farnell GF, Buckner J, Cascino TL et al. Brain metastases from colorectalcarcinoma. The long term survivors. Cancer 1996; 78: 711-716
330. Schoeggl A, Kitz K, Reddy M et al. Stereotactic radiosurgery for brain metastases from colorectal cancer. Int J Colorectal Dis 2002; 17: 150-155